Compounds inhibiting cholinesterases are considered as potential agents for the treatment of a number of diseases associated with abnormality in cholinergic neurotransmission (Alzheimer’s disease, myasthenia gravis, etc.). This evidence concerns the gene BCHE and myasthenia gravis.